Skip to main content
Clinical Trials/CTRI/2023/06/054482
CTRI/2023/06/054482
Completed
未知

Assessment of triglyceride glucose index in patients with non alcoholic fatty liver disease & its correlation with the disease severity. - NI

Tushar Akare0 sites105 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
Sponsor
Tushar Akare
Enrollment
105
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
July 15, 2024
Last Updated
last year
Study Type
Observational

Investigators

Sponsor
Tushar Akare

Eligibility Criteria

Inclusion Criteria

  • Evidence of fatty liver on ultrasonography of abdomen.
  • Patients who satisfy the European Association for the Study of the Liver Criteria (EASL criteria) for NAFLD will be recruited for the study.
  • EASL criteria for NAFLD is alcohol consumption less than 30 g/day for men and less than 20 g/day for women.
  • Age \>18 years and \<65 years of any gender.

Exclusion Criteria

  • Subjects having significant alcohol consumption (more than 30 gm/day in case of males and more than 20 gm/day in case of females)
  • Pregnant or lactating women
  • Subjects carrying hepatitis B and/or hepatitis C virus infection
  • Patients with autoimmune hepatic disease
  • Other chronic hepatic diseases i.e. Wilson’s disease, hereditary hemochromatosis, primary billiary cirrhosis etc.
  • Patients on drugs that can lead to fatty liver e.g. methotrexate, amiodarone, anti\- retroviral drugs, tamoxifene, barium salts, tetracycline, Estrogen, glucocorticoids, etc.
  • Individuals having DM, metabolic syndrome, dyslipidemia and/or hypothyroidism
  • Individuals having significant alcohol consumption and/or CLD
  • Pregnant or lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials